A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
- 16 June 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 35 (10), 2072-2082
- https://doi.org/10.1038/npp.2010.79
Abstract
Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N=514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p=0.02; 100 mg equiv., pp0.006) and PANSS negative and positive symptom Marder factor scores (p0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5–6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia.This publication has 33 references indexed in Scilit:
- Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInternational Clinical Psychopharmacology, 2010
- Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInternational Journal of Neuropsychopharmacology, 2009
- Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophreniaCurrent Medical Research and Opinion, 2009
- Switching to Long-Acting Injectable Risperidone is Beneficial with Regard to Clinical Outcomes, Regardless of Previous Conventional Medication in Patients with SchizophreniaPharmacopsychiatry, 2007
- A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophreniaInternational Clinical Psychopharmacology, 2007
- The case for long‐acting antipsychotic agents in the post‐CATIE eraActa Psychiatrica Scandinavica, 2007
- Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With SchizophreniaJournal of Clinical Psychopharmacology, 2007
- Early Clinical Experience With Risperidone Long-Acting InjectionPublished by Physicians Postgraduate Press, Inc ,2004
- Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioningActa Psychiatrica Scandinavica, 2000
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970